Disease Domain | Count |
---|---|
Neoplasms | 12 |
Hemic and Lymphatic Diseases | 5 |
Immune System Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Proteolysis-targeting chimeras | 4 |
Autologous CAR-T | 1 |
Molecular glue | 1 |
T-lymphocyte cell therapy | 1 |
Target |
Mechanism CD19 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK12 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date20 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CD19/CD20 CAR-T (Fujian Medical University) ( CD19 x CD20 ) | Diffuse large B-cell lymphoma recurrent More | Phase 1 |
Chimeric Natural Killer Receptor-Universal T Cells(Fujian Medical University) | Steroid Refractory Graft Versus Host Disease More | Phase 1 |
Koumine Hydrochloride | Rheumatoid Arthritis More | IND Approval |
DC-BPi-07 ( BPTF ) | Neoplasms More | Preclinical |
C1206 ( HSP90 ) | Philadelphia chromosome positive chronic myelogenous leukemia More | Preclinical |